Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

NCT05883748 is registered in ClinicalTrials.gov with Disc Medicine, Inc as lead sponsor.

NCT NCT05883748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05883748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
Lead sponsor
Disc Medicine, Inc
Phase
Phase 2/3
Overall status
Enrolling by invitation
Start date
August 31, 2023
Completion date
June 30, 2028
Enrollment
230 (estimated)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

erythropoietic protoporphyria